MBD4 and colorectal carcinoma: In order to test the hypothesis that MBD4 alterations are not only secondary to MSI in MMR-deficient tumors and may be selected for during tumorigenesis, we evaluated the frequency of pathogenic and likely non-pathogenic MBD4 variants, as determined by in silico prediction, in a cohort of unselected CRC cases (n = 1536), from COSMIC and cBioPortal databases, and control samples (n = 6503), from the Exome Variant Server (http://evs.gs.washington.edu/EVS/).